Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

Information for patients

The website you have tried to access contains clinical information designed specifically for medical professionals experienced in treating this condition. If you have any questions about your health or treatment, please consult your doctor.

 

Astellas
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

The patient perspective

  • The burden on patients

    Anaemia of CKD has a substantial impact on patients’ lives1

    It is associated with poor clinical outcomes and reduced quality of life.1,2

    Patient perspective1

    Symptoms of anaemia overlap with those of CKD1 and may add to the burden of CKD.2

    Untreated anaemia may accelerate progression of CKD.1,3

    Current management of CKD can be sub-optimal2,4

    Some patients with anaemia of CKD are not treated to target3-5

    Concern about the risks of over-correcting haemoglobin may lead to under-treatment of patients.4

    How does it feel to live with anaemia of CKD?

    Effective control of Hb?

    Image of smiling man painting chair

    Convenience?

    Image of smiling woman

    Tolerability?

    Image of man holding plant(close up)

    CKD, chronic kidney disease; GI, gastrointestinal; Hb, haemoglobin.

    References

    • Mathias SD et al. J Patient-Reported Outcomes. 2020;4,64. https://doi.org/10.1186/s41687-020-00215-8.
    • Guedes M et al. Kidney360. 2020;(1):855-62.
    • Dowling TC. Am J Health-System Pharmacy. 2007;64(13 suppl 8):S3–S7.
    • Lopes MB et al. Nature Scientific Reports. 2021;11:1784. https://doi.org/10.1038/s41598-020-79254-6.
    • Stauffer ME, Fan T. PLoS ONE. 2014;9(1):e84943. doi:10.1371/journal.pone.0084943.

    • Patient benefits of EVRENZO

      EVRENZO helps CKD patients achieve and maintain Hb targets1

      At home with their treatment.

      Oral treatment that can be taken at home1

      • no special storage instructions1

      • no need to administer in hospital1

      Image of guitar being played (close up)

      Three times weekly dosage1

      Image of woman watering plants (close up)

      Reduced use of IV iron compared with ESA1

      Image of smiling man painting chair

      CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; IV, intravenous; NDD, non-dialysis-dependent; TIW, three times weekly.

      Reference

      • EVRENZO SmPC.

      • Which of your patients will benefit most?

        Non-dialysis patients

        Image of man holding plant (close up)

        Routine oral iron
        Iron replete
        Hb below target
        Poor adherence to oral iron

        Image of smiling woman

        Routine IV iron
        Iron replete
        Hb below target
        Difficulty attending
        clinic for IV iron


        EVRENZO is an oral tablet that provides Hb correction and maintenance superior to placebo (p<0.0001) and comparable to ESA (p=0.844), with reduced use of IV iron1

        Just started dialysis

        Image of smiling man painting chair

        Routine iron
        Iron replete
        Hb below target


        EVRENZO is an oral tablet that provides comparable Hb correction (95% CI; 0.28 [0.110, 0.451]) and maintenance (95% CI; 0.30 [0.228, 0.373]) to ESA, with reduced use of IV iron1


        How can your patients get more out of EVRENZO?

        The leaflets below provide educational materials and simple advice to support patients during their treatment journey.

        EVRENZO disease education booklet image

        Disease education booklet

        A general information for patients having anaemia of CKD, information about what is anaemia, symptoms, tests etc, and include a diary for the patients to make their notes for the next clinic visit

        DOWNLOAD

        DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.

        Reference

        • EVRENZO SmPC.



        EVRENZO™ (roxadustat), 20, 50, 70, 100 och 150 mg filmdragerade tabletter, B03XA05, Rx (särskilt läkemedel), F

        Indikationen är behandling av vuxna patienter med symtomatisk anemi associerad med kronisk njursjukdom (CKD). Kontraindikationer är överkänslighet mot den aktiva substansen, jordnötter, soja eller hjälpämne, användning under graviditetens tredje trimester samt amning. Varningar och försiktighet inkluderar risk för allvarliga (inklusive dödliga) kardiovaskulära och trombovaskulära händelser, inklusive cerebral infarkt, djup ventrombos och lungemboli, krampanfall och allvarliga infektioner, inklusive sepsis. Ska inte sättas in hos kvinnor som planerar att bli gravida eller under graviditet. Fertila kvinnor måste använda en högeffektiv preventivmetod under behandling och i minst en vecka efter sista dosen. Försiktighet gällande administrering krävs vid måttligt nedsatt leverfunktion och rekommenderas inte vid kraftigt nedsatt leverfunktion. Felanvändning kan leda till en överdrivet förhöjd hematokrit vilket kan leda till livshotande komplikationer i hjärt-kärlsystemet.

        Astellas Pharma AB, Tel: 040-650 15 00, 200 21 Malmö. Produktresumé 2026-03.

        För ytterligare information och förpackningar se www.fass.se.